+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Keloids - Pipeline Review, H1 2020

  • ID: 5130298
  • Drug Pipelines
  • June 2020
  • Region: Global
  • 64 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Allianz Pharmascience Ltd
  • FBM Therapeutics LLC
  • FirstString Research Inc
  • Lemonex Inc
  • Miragen Therapeutics Inc
  • Next Science Ltd
  • MORE
Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Keloids - Pipeline Review, H1 2020, provides an overview of the Keloids (Dermatology) pipeline landscape.

Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Keloids - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Keloids (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keloids (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 4, 1 and 1 respectively.

Keloids (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Keloids (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keloids (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keloids (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keloids (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keloids (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Allianz Pharmascience Ltd
  • FBM Therapeutics LLC
  • FirstString Research Inc
  • Lemonex Inc
  • Miragen Therapeutics Inc
  • Next Science Ltd
  • MORE
  • Introduction
  • Report Coverage
  • Keloids - Overview
  • Keloids - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Keloids - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Keloids - Companies Involved in Therapeutics Development
  • Allianz Pharmascience Ltd
  • FBM Therapeutics LLC
  • FirstString Research Inc
  • Lemonex Inc
  • Miragen Therapeutics Inc
  • Next Science Ltd
  • Phio Pharmaceuticals Corp
  • siRNAgen Therapeutics Corp
  • Sirnaomics Inc
  • Tumorend LLC
  • Yuhan Corp
  • Keloids - Drug Profiles
  • ALZ-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Antisense RNAi Oligonucleotide to Inhibit Amphiregulin for Hypertrophied scar and Keloid - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CM-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drug for Keloids - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FBM-5712 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Granexin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LEM-S401 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remlarsen - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RXI-109 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • STP-705 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YHC-1113 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Keloids - Dormant Projects
  • Keloids - Discontinued Products
  • Keloids - Product Development Milestones
  • Featured News & Press Releases
  • Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
  • Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
  • Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
  • Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
  • Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
  • Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109
  • Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Keloids, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Keloids - Pipeline by Allianz Pharmascience Ltd, H1 2020
  • Keloids - Pipeline by FBM Therapeutics LLC, H1 2020
  • Keloids - Pipeline by FirstString Research Inc, H1 2020
  • Keloids - Pipeline by Lemonex Inc, H1 2020
  • Keloids - Pipeline by Miragen Therapeutics Inc, H1 2020
  • Keloids - Pipeline by Next Science Ltd, H1 2020
  • Keloids - Pipeline by Phio Pharmaceuticals Corp, H1 2020
  • Keloids - Pipeline by siRNAgen Therapeutics Corp, H1 2020
  • Keloids - Pipeline by Sirnaomics Inc, H1 2020
  • Keloids - Pipeline by Tumorend LLC, H1 2020
  • Keloids - Pipeline by Yuhan Corp, H1 2020
  • Keloids - Dormant Projects, H1 2020
  • Keloids - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Keloids, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
  • Allianz Pharmascience Ltd
  • FBM Therapeutics LLC
  • FirstString Research Inc
  • Lemonex Inc
  • Miragen Therapeutics Inc
  • Next Science Ltd
  • Phio Pharmaceuticals Corp
  • siRNAgen Therapeutics Corp
  • Sirnaomics Inc
  • Tumorend LLC
  • Yuhan Corp
Note: Product cover images may vary from those shown
Adroll
adroll